Bile Acids and Gut Microbiota as Potent Coronary Atheroma Risk Factors: a Prospective Study in Human
MABAC
The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)
1 other identifier
observational
80
1 country
1
Brief Summary
The purpose of this study is to describe the composition of bile acids and the gut microbiota comparing two populations: patients with coronary atheroma and the healthy subjects. Our hypothesis is based on the demonstration of the anti atherogenic and anti inflammatory effect of certain bile acids, and the role of the gut microbiota in the metabolic regulation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
February 24, 2015
CompletedFirst Posted
Study publicly available on registry
March 3, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedNovember 20, 2025
October 1, 2025
10 months
February 24, 2015
November 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Gut microbiota composition in coronary patients versus healthy subject
Observational only
8 months
Secondary Outcomes (1)
Bile acids composition in coronary patients versus healthy subjects, in feces and blood samples
8 months
Study Arms (2)
Coronary patients
Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
Healthy subjects (2)
Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
Interventions
Eligibility Criteria
Tertiary care center: cardiology unit.
You may qualify if:
- \- All patients admitted for a coronary angiogram
You may not qualify if:
- Statins, hypolipemic drugs, corticoids, anti HIV drugs
- Antibiotics adminisitration in the last 3 months
- Past of cholecystectomy
- Hepatic disorders
- Acute coronary syndrome
- No agreement, Insufficiency in comprehension
- Non fasting for at least 8 hours
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cardiology Department, Cochin Hospital
Paris, 75014, France
Related Publications (1)
Chong Nguyen C, Duboc D, Rainteau D, Sokol H, Humbert L, Seksik P, Bellino A, Abdoul H, Bouazza N, Treluyer JM, Saadi M, Wahbi K, Soliman H, Coffin B, Bado A, Le Gall M, Varenne O, Duboc H. Circulating bile acids concentration is predictive of coronary artery disease in human. Sci Rep. 2021 Nov 22;11(1):22661. doi: 10.1038/s41598-021-02144-y.
PMID: 34811445RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Denis Duboc, MD, PhD
APHP
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 24, 2015
First Posted
March 3, 2015
Study Start
February 1, 2015
Primary Completion
December 1, 2015
Study Completion
December 1, 2015
Last Updated
November 20, 2025
Record last verified: 2025-10